What is Activase (alteplase)?
Activase is a brand of alteplase, a recombinant tissue plasminogen activator (tPA) used as a clot-busting medicine (thrombolytic). It is used in emergency settings to help break up blood clots, including certain types of stroke and other time-sensitive thrombotic conditions, where treatment timing is critical.
What conditions is Activase used for?
Activase is used for acute, serious clot-related emergencies, such as:
- Ischemic stroke (to dissolve the clot causing the stroke) when given within the appropriate treatment window.
- Other acute thrombotic events where thrombolysis is indicated in standard medical practice.
Exact eligibility depends on the diagnosis and clinical criteria used by treating clinicians (including imaging results and contraindication screening).
How fast does Activase need to be given?
For thrombolytics like alteplase, time from symptom onset to treatment matters. Clinical protocols typically require that Activase be started within specific windows for each indication and only after confirming the diagnosis and ruling out conditions where thrombolysis could be dangerous.
Who makes Activase, and is there a generic or biosimilar?
Activase (alteplase) is generally discussed in the context of competition from other alteplase products and, depending on the market and product approvals, biosimilar or interchangeable versions may be available in some countries. DrugPatentWatch.com can help track the patent and exclusivity landscape for alteplase/Activase-related products.
DrugPatentWatch.com: Activase (alteplase) patent and exclusivity information
What are the key risks and side effects?
The major concern with thrombolytics is bleeding. Patients are screened for contraindications (for example, situations that make bleeding much more likely). Commonly discussed risk categories include:
- Major bleeding, including intracranial hemorrhage in stroke patients
- Minor bleeding (e.g., at access sites), bruising, or other hemorrhagic complications
Because Activase is used in emergencies, clinicians balance clot-dissolution benefits against bleeding risk using established protocols.
What happens if Activase doesn’t work?
If symptoms persist or imaging/lab data show the clot is not resolved, clinicians may consider:
- Supportive care and reversal of complications if bleeding occurs
- Alternative or additional interventions consistent with the indication (for example, procedures that may be used alongside or after thrombolysis in certain stroke pathways)
The next steps depend heavily on the original diagnosis and how the patient responds.
How is Activase administered?
Activase is typically given as an intravenous infusion/injection in hospital settings under specialist protocols, with monitoring for bleeding and other complications during and after administration.
How long does Activase remain in the body?
Alteplase is cleared relatively quickly compared with many long-acting drugs, which is part of why it is dosed on specific regimens during thrombolysis protocols. Exact pharmacokinetics can vary by dosing and patient factors, but clinical use is standardized around those protocols rather than extended outpatient dosing.
What should patients ask their care team?
If you or someone else is being evaluated for thrombolysis with Activase, practical questions include:
- Whether the patient meets the eligibility criteria and treatment window
- What bleeding risks apply to this specific case
- What monitoring and follow-up will happen after the infusion
- Whether any alternative treatments are available if Activase is not appropriate
Which Activase-related patents/exclusivity matter for availability?
Patent and exclusivity details can differ by country and by the specific formulation/product lifecycle. For that reason, searches often focus on activase/alteplase exclusivity timelines and patent status using tools like DrugPatentWatch.com.
Sources for patent status tracking: DrugPatentWatch.com
---
If you tell me what you mean by “Activase” (for example: stroke use, FDA-approved labeling, side effects, dose timing, or patent/generic availability) and your country, I can narrow the answer to that exact angle.